NO20076040L - Nye laktam-sammensetninger - Google Patents

Nye laktam-sammensetninger

Info

Publication number
NO20076040L
NO20076040L NO20076040A NO20076040A NO20076040L NO 20076040 L NO20076040 L NO 20076040L NO 20076040 A NO20076040 A NO 20076040A NO 20076040 A NO20076040 A NO 20076040A NO 20076040 L NO20076040 L NO 20076040L
Authority
NO
Norway
Prior art keywords
diabetic
new lactam
present
provides
new
Prior art date
Application number
NO20076040A
Other languages
English (en)
Inventor
Itsuya Tanabe
Hideyuki Tanaka
Wataru Miyanaga
Masaru Takayanagi
Ryusuke Hirama
Yoko Kageyama
Tatsuya Ishikawa
Yoriko Okamatsu
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of NO20076040L publication Critical patent/NO20076040L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Den foreliggende oppfinnelsen tilveiebringer nye laktamforbindelser i følge formel (1), et sukkertransportforsterkende middel inneholdende disse forbindelsene som en aktiv ingrediens, et middel for forebyggingen og/eller behandlingen av diabetes mellitus, diabetisk perifer neuropati, diabetisk nefropati, diabetisk retinopati, diabetisk makrovaskulær sykdom, glukose toleranseanomali, fedme og lignende. I tillegg tilveiebringer den foreliggende oppfinnelsen en ny fremgangsmåte, og et intermediat, for fremstilling av de nye laktamforbindelsene.
NO20076040A 2005-04-28 2007-11-23 Nye laktam-sammensetninger NO20076040L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005130879 2005-04-28
PCT/JP2006/309349 WO2006118341A1 (ja) 2005-04-28 2006-04-28 新規ラクタム化合物

Publications (1)

Publication Number Publication Date
NO20076040L true NO20076040L (no) 2008-01-28

Family

ID=37308118

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20076040A NO20076040L (no) 2005-04-28 2007-11-23 Nye laktam-sammensetninger

Country Status (14)

Country Link
US (1) US7951799B2 (no)
EP (1) EP1878734A4 (no)
JP (1) JP5056412B2 (no)
KR (1) KR20080004632A (no)
CN (1) CN101166742B (no)
AU (1) AU2006241684A1 (no)
BR (1) BRPI0610034A2 (no)
CA (1) CA2607506A1 (no)
IL (1) IL186972A0 (no)
NO (1) NO20076040L (no)
NZ (2) NZ563131A (no)
RU (1) RU2007144076A (no)
WO (1) WO2006118341A1 (no)
ZA (1) ZA200709235B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2544310A1 (en) * 2003-10-31 2005-05-12 Ajinomoto Co., Inc. New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
JP5672699B2 (ja) 2007-04-11 2015-02-18 味の素株式会社 血糖降下作用化合物のスクリーニング法
WO2008139576A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の製造方法及びその製造中間体
WO2008139574A1 (ja) * 2007-04-27 2008-11-20 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
WO2008136393A1 (ja) * 2007-04-27 2008-11-13 Ajinomoto Co., Inc. ラクタム化合物の結晶形およびその製造方法
JP2012180282A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
JP2012180283A (ja) * 2009-07-02 2012-09-20 Ajinomoto Co Inc ラクタム化合物の製造方法およびその製造中間体
PT2661266T (pt) 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US9795792B2 (en) 2011-02-25 2017-10-24 Medtronic, Inc. Emergency mode switching for non-pacing modes
SG10201901922VA (en) 2012-01-06 2019-04-29 Elcelyx Therapeutics Inc Compositions and methods for treating metabolic disorders
MX2014008190A (es) 2012-01-06 2015-02-04 Elcelyx Therapeutics Inc Composiciones de biguanida y métodos para tratar transtornos metabólicos.
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EA039530B1 (ru) 2013-01-05 2022-02-08 Анджи Фарма (Юс) Элэлси Композиция с отсроченным высвобождением, содержащая бигуанид

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI234557B (en) 1999-05-26 2005-06-21 Telik Inc Novel naphthalene ureas as glucose uptake enhancers
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
CN100577651C (zh) 2000-12-01 2010-01-06 味之素株式会社 内酰胺化合物及其药物用途
JP4345097B2 (ja) * 2002-06-05 2009-10-14 味の素株式会社 縮合多環式化合物およびその医薬用途
BRPI0407303A (pt) 2003-02-07 2006-02-07 Ajinomoto Kk Composição farmacêutica
CA2544310A1 (en) * 2003-10-31 2005-05-12 Ajinomoto Co., Inc. New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
EP1707567A4 (en) 2004-01-14 2009-08-19 Ajinomoto Kk NEW FUSED CYCLE COMPOUND

Also Published As

Publication number Publication date
EP1878734A1 (en) 2008-01-16
RU2007144076A (ru) 2009-06-10
EP1878734A4 (en) 2010-02-17
CN101166742B (zh) 2011-07-13
CN101166742A (zh) 2008-04-23
IL186972A0 (en) 2008-02-09
NZ563131A (en) 2010-09-30
KR20080004632A (ko) 2008-01-09
ZA200709235B (en) 2009-09-30
US20080108604A1 (en) 2008-05-08
JP5056412B2 (ja) 2012-10-24
US7951799B2 (en) 2011-05-31
BRPI0610034A2 (pt) 2011-10-18
WO2006118341A1 (ja) 2006-11-09
CA2607506A1 (en) 2006-11-09
NZ587672A (en) 2011-12-22
AU2006241684A1 (en) 2006-11-09
JPWO2006118341A1 (ja) 2008-12-18

Similar Documents

Publication Publication Date Title
Huigens et al. Inhibition of Pseudomonas aeruginosa biofilm formation with bromoageliferin analogues
NO20081212L (no) Xantinderivater som selektive HM74A agonister
WO2007041365A3 (en) 3-cyclyl-2- (4-sulfamo yl-phenyl) -n-cyclyl-propionamide derivatives useful in the treatment of impaired glucose tolerance and diabetes
NO20051585L (no) Stabilized exendin-4 compounds
NO20084874L (no) Piendinylsubstituerte pyrrolidinoner som hemmere av 11-beta-hydroksysteroiddehydrogenase 1
NO20055680L (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
EA201100266A1 (ru) Диокса-бицикло[3.2.1]октан-2,3,4-триольные производные
NO20065926L (no) Substituerte oksazolbenzoisotiazoldioksidderivater samt fremgangsmate for fremstilling og anvendelse derav
NO20085056L (no) Insulinderivat
NO20084318L (no) Inhibitorer av II-beta-hydroksystereoid dehydrogenase I
WO2008051272A3 (en) Somatostatin agonists
TNSN06315A1 (en) Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes
NO20056010L (no) Biaryloksymetylaren-karboksylsyrer
NO20073806L (no) Substituerte pyridinyl og pyrimidinylderivater som modulatorer av metabolisme og behandling av lidelser relatert til dette
NO20072389L (no) Substituerte benzokinolizinderivater
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
NO20082496L (no) Pyrazinderivater
WO2006099941A8 (de) Aminocarbonyl substituierte 8-n-benzimidazole, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
NO20092691L (no) 4-hydroksy-2-okso-2,3-dihydro-1,3-benzotiazol-7yl-forbindelser for modulering av B2-adrenoreseptoraktivitet
NO20050932L (no) 1-pyridin-4-yl-ureaderivater
NO20083065L (no) Nye N-sulfamoylpiperidinamider for profylakse eller behandling av overvekt og beslektede tilstander
MX2010009536A (es) Amidas de acido 5-oxo-2,3,4,5-tetrahidro-benzo[b]oxepin-4-carboxil ico y amidas de acido 2,3-dihidro-benzo[b]oxepin-4-carboxilico para el tratamiento y la prevension de la diabetes tipo 1 y 2.
WO2018169282A3 (ko) Atpif1을 함유하는 당뇨 치료용 약학조성물
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
TW200616985A (en) Salicylthiazoles substituted by diphenylamine or diphenylamine derivatives, process for their preparation and their use

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application